Sugi Predict

Sugi Predict / Compounds / SCHEMBL20396083

SCHEMBL20396083

SCHEMBL20396083

CC(C)(C)OC(=O)N1CCC2(C=C(B3OC(C)(C)C(C)(C)O3)C2)CC1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TSHR P16473 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ GPR119 Q8TDV5 4/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RECQL P46063 1/20 0.35
▸ BUB1 O43683 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23931453 0.93 USP30 (0.41) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL23931390 0.87 USP30 (0.41) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL24753436 0.82 USP30 (0.40) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL20396153 0.82 USP30 (0.40) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL23584405 0.82 USP30 (0.40) USP30USP2SMN1; SMN2MAPTGPR119
SCHEMBL16051476 0.80 USP30 (0.40) USP30USP2SMN1; SMN2GPR119
SCHEMBL23931417 0.79 USP30 (0.39) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL26133794 0.78 USP30 (0.39) USP30USP2SMN1; SMN2ALDH1A1LMNA
SCHEMBL19693266 0.78 SCD5 (0.42) USP30USP2SMN1; SMN2GPR119
SCHEMBL10179664 0.78 P2RX7 (0.46) USP30USP2SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096858-A1 COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
WO-2025077671-A1 POLYSUBSTITUTED ARYL DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2025-04-17 — — WO disclosed
WO-2023241684-A1 PDE4B INHIBITOR 武汉人福创新药物研发中心有限公司 2023-12-21 — — WO disclosed
US-20230122249-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-20 — — US disclosed
EP-3704114-B1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-11-23 — — EP disclosed
WO-2021216661-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 — — WO disclosed
WO-2021216661-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV ASSEMBLY BIOSCIENCES, INC. (US) 2021-10-28 — — WO disclosed
WO-2021154663-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-05 — — WO disclosed
US-11078198-B2 Spirocyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2021-08-03 — — US disclosed
EP-3704114-A1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2020-09-09 — — EP disclosed
US-10626125-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors PFIZER INC. (US) 2020-04-21 — — US disclosed
WO-2019228404-A1 NOVEL PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF 信达生物制药(苏州)有限公司 (CN) 2019-12-05 — — WO disclosed
US-20190276472-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS PFIZER INC. (US) 2019-09-12 — — US disclosed
US-10329308-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors PFIZER INC. (US) 2019-06-25 — — US disclosed
US-20190127362-A1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 — — US disclosed
US-20180208607-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS PFIZER INC. (US) 2018-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276472-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS MAG, PYM1, HIF1AN USP30 3440/4885USP2 4400/4885SMN1; SMN2 1148/4885
US-20190127362-A1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS NR1H4, FXR1, NR1H2 USP30 4711/4885USP2 4778/4885SMN1; SMN2 4433/4885
US-11078198-B2 Spirocyclic compounds as farnesoid X receptor modulators NR1H4, FXR1, NR1H2 USP30 4711/4885USP2 4778/4885SMN1; SMN2 4433/4885
US-10626125-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors MAG, PYM1, HIF1AN USP30 3440/4885USP2 4400/4885SMN1; SMN2 1148/4885
US-20180208607-A1 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS MAG, PYM1, HIF1AN USP30 3440/4885USP2 4400/4885SMN1; SMN2 1148/4885
US-10329308-B2 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors MAG, PYM1, HIF1AN USP30 3440/4885USP2 4400/4885SMN1; SMN2 1148/4885
US-20230122249-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR9, TLR1 USP30 4364/4885USP2 4362/4885SMN1; SMN2 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback